Abstract

There is an association between diabetes and impaired bone healing. The purpose of this study was to determine whether sericin had a positive effect on bone regeneration with streptozotocin-induced diabetes in a rat model. Sprague Dawley rats (n = 21) were assigned to one of three groups. A critical-sized bone defect was created on the calvaria. In the sericin group (S group, n = 7), the bone defect was filled with a sericin–gelatin combination, whereas in the gelatin group (G group, n = 7), only gelatin sponge was used. The control group (N group, n = 7) did not receive any graft. New bone formation was evaluated by micro-computerized tomogram and histological analysis. The regenerated bone volume in group S was the highest among the three groups (3.87 ± 2.51 mm3), followed by group N (1.71 ± 1.65 mm3) and group G (1.24 ± 1.05 mm3). The application of sericin in combination with a gelatin sponge enhanced the process of bone regeneration in streptozotocin-induced type I diabetes animal model.

Highlights

  • The purpose of this study was to evaluate the effect of sericin on bone regeneration of critical-sized defects in an STZ-induced type 1 diabetic animal model

  • Silk mat, which is the combination of sericin and fibroin, has increased bone regeneration in clinical trials [22]

  • According to microcomputerized tomogram (microCT) and histological analysis, group S showed more new bone formation compared to group G and group N (Tables 1 and 2)

Read more

Summary

Introduction

Diabetes mellitus (DM) is a chronic disease showing an increased sugar level in blood over a prolonged period. Chronic complications are cardiovascular disease, kidney failure, neuropathy, and diabetic feet [2]. There has been a long-standing concern about the association between diabetes and bone health. This issue was first suggested nearly a century ago by studying the radiological feature of decelerated bone development and bone atrophy in type 1 diabetes children [3]. Delays in bone union or increases in healing time are features that are most commonly observed when comparing diabetic subjects with matched controls, in clinical studies [5]

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call